CHAINON NEUROTROPHIN ENTERPRISES

CHAINON NEUROTROPHIN BIOTECHNOLOGY, INC. (Chainon) is a start-up nutraceutical company focused on the discovery, development and commercialization of orally administered proprietary highly enriched docosahexaenoic acid (DHA; n-3 22:6) - containing phospholipid and alkyl ether phospholipid nutrients, as well as phospholipid drug candidates that target (i) neural membrane and neurotrophin receptors to promote survival of aged basal forebrain cholinergic neurons (BFCNs) in order to prevent and treat age-dependent basal forebrain cholinergic neuron dysfunction related neurodegenerative disorders, (ii) modify fluidity of neural membranes and membrane anti-oxidation by providing brain DHA and ether phospholipid precursors, and (iii) human productive system in order to improve male fertility by enhancing the mobility of human spermatozoa... The Chainon is a leader in a powerful area called "mechanism-based" discovery of DHA - containing phospholipids and DHA - containing ether phospholipids..

Also known as: CHAINON NEUROTROPHIN BIOTECHNOLOGY, INC., Chainon Neurotrophin Enterprises Ltd, The Chainon

Primary location: Auckland New Zealand